Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).

Alessandra NarcisiMario Valenti Luigi Gargiulo Luciano IbbaFabrizio AmorusoGiuseppe ArgenzianoFederico BardazziMartina BurlandoCarlo Giovanni CarreraGiovanni DamianiPaolo DapavoValentina DiniChiara FranchiGiampiero GirolomoniClaudio GuarneriFrancesco LoconsoleFrancesca SampognaMassimo TravagliniPiergiorgio MalagoliAntonio Costanzo

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)

Our data suggest that the efficacy of tildrakizumab for plaque psoriasis in 'real-life' clinical practice is comparable with Phase 3 clinical trials with higher percentages of patients achieving complete skin clearance (PASI 100) at Weeks 16, 28 and 52.

Keyphrases

clinical trial
clinical practice
end stage renal disease
coronary artery disease
ejection fraction
newly diagnosed
systematic review
prognostic factors
atopic dermatitis
electronic health record
big data
machine learning
cross sectional
phase ii
open label
data analysis
drug induced